Lanthanum carbonate

Therapy

Volumn 2, Issue 4, 2005, Pages 545-557

  Finn, William F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Calcification; Chronic renal failure; Hemodialysis lanthanum carbonate; Osteomalacia; Phospate; Renal osteodystrophy

Indexed keywords

ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SALT; DIGOXIN; LANTHANUM CARBONATE; METOPROLOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; WARFARIN;

ACIDOSIS; ADJUVANT THERAPY; ALBRIGHT SYNDROME; ANEMIA; BONE DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIARRHEA; DIET SUPPLEMENTATION; DISEASE CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MORTALITY; NAUSEA; NONHUMAN; OSTEOMALACIA; PH; PHARMACODYNAMICS; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SOFT TISSUE CALCIFICATION; VOMITING;

EID: 22544435510     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.4.545     Document Type: Review

References (77)

1. Martin KJ, Gonzalez EA. Strategies to minimize bone disease in renal failure. Am. J. Kidney Dis. 38(6), 1430-1436 (2001).
2. Silver J. Pathogenesis of parathyroid dysfunction in end-stage renal disease. Adv. Ren. Replace. Ther. 9(3), 159-167 (2002).
3. Zabetakis PM, Nissenson AR. Complications of chronic renal insufficiency: beyond cardiovascular disease. Am. J. Kidney Dis. 36(6 Suppl. 3), S31-S38 (2000).
4. Kates DM, Sherrard DJ, Andress DL. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am. J. Kidney Dis. 30(6), 809-813 (1997).
5. Lopez-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am. J. Physiol. 259(3 Pt 2), F432-F437 (1990).
6. Slatopolsky E, Dusso A, Brown AJ. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am. J. Med. Sci. 317(6), 370-376 (1999).
7. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. 35(6), 1226-1237 (2000).
8. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342(20), 1478-1483 (2000).
9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31(4), 607-617 (1998).
10. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15(8), 2208-2218 (2004).
11. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 91(1), 103-111 (2002).
12. Coburn JW, Elangovan L. Prevention of metabolic bone disease in the pre-endstage renal disease setting. J. Am. Soc. Nephrol. 9(Suppl. 12), S71-S77 (1998).
13. Kaye M, Turner M, Ardila M, Wiegmann T, Hodsman A. Aluminum and phosphate. Kidney Int. Suppl. 24, S172-S174 (1988).
14. Rufino M, de Bonis E, Martin M et al. Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol. Dial. Transplant. 13(Suppl. 3), 65-67 (1998).
15. Morton R, Hercz G, Coburn J. Control of hyperphosphatemia in chronic renal failure. Semin. Dial. 3, 219-223 (1990).
16. Hercz G, Coburn JW. Prevention of phosphate retention and hyperphosphatemia in uremia. Kidney Int. Suppl. 22, S215-S220 (1987).
17. Hou SH, Zhao J, Ellman CF et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am. J. Kidney Dis. 18(2), 217-224 (1991).
18. National Kidney Foundation. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am. J. Kidney Dis. 41(4 Suppl. 3), I-I91 (2003).
19. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin. Nephrol. 54(4), 318-324 (2000).
20. McGonigle RJ, Parsons V. Aluminium-induced anaemia in hemodialysis patients. Nephron 39(1), 1-9 (1985).
21. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1(8113), 406-409 (1979).
22. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N. Engl. J. Med. 294, 184-188 (1976).
23. Goodman WG. Bone disease and aluminum: pathogenic considerations. Am. J. Kidney Dis. 6(5), 330-335 (1985).
24. Ihle BU, Becker GJ, Kincaid-Smith PS. Clinical and biochemical features of aluminum-related bone disease. Kidney Int. Suppl. 18, S80-S86 (1986).
25. Malluche HH. Aluminum and bone disease in chronic renal failure. Nephrol. Dial. Transplant. 17(Suppl. 2), 21-24 (2002).
26. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. 315(3), 157-161 (1986).
27. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 26(15), 1093-1115 (2003).
28. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. 12(8), 1640-1644 (1997).
29. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol. Dial. Transplant. 14(12), 2907-2914 (1999).
30. Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel®): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. 29(1), 66-71 (1997).
31. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 62(1), 245-252 (2002).
32. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 55(1), 299-307 (1999).
33. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(4 Suppl. 3), 1-201 (2003).
34. Borras M, Marco MP, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit. Dial. Int. 22(6), 737-738 (2002).
35. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int. 57(4), 1776-1777 (2000).
36. Block GA, Sakiewicz PG. Serum bicarbonate levels with sevelamer versus calcium containing phosphate binders in hemodialysis patients. Presented at the ASN/ISN World Congress of Nephrology. CA, USA, 10-17 October 2001.
37. Niinisto L. Swedish contributions to the discovery of F-elements: Part 3: The work of Masander, Cleve and Nilson. ERES Newsletter 12, 2-4 (2001).
38. Locatelli F, D'Amico M, Pontoriero G. Lanthanum carbonate (Shire). IDrugs 6(7), 688-695 (2003).
39. Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr. Opin. Nephrol. Hypertens. 13(4), 403-409 (2004).
40. Damment SJP, Webster I. The pharmacology of lanthanum carbonate (Fosrenol®): a novel nonaluminium, noncalcium phosphate binder. J. Am. Soc. Nephrol. 14, 204A (2003).
41. Damment SJP, Totten W. The pharmacology of a new phosphate binder, lanthanum carbonate. Presented at the World Congress of Nephrology Clinical Meeting. Berlin, Germany, 8-12 June 2003.
42. Damment SJP, Gill M. The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol®), a new nonaluminium, noncalcium phosphate binder. J. Am. Soc. Nephrol. 14, 204A (2003).
43. Pennick M, Damment SJP, Gill M. The new nonaluminium, noncalcium phosphate binder, lanthanum carbonate, demonstrates pharmacokinetics favourable for use in a chronic kidney disease population. Presented at the 41st Congress of the European Renal Association and European Dialysis and Transplant Association. Lisbon, Portugal, 15-18 May 2004.
44. Morie T, Iwamoto M, Harada N, Masumoto S, Yamada M, Kusunose Y. Urinary excretion of aluminum: effects of aging and diurnal variation. Arch. Gerontol. Geriatr. 22(3), 287-295 (1996).
45. Kato M, Sugihara J, Nakamura T, Muto Y. Electron microscopic study of the blood-brain barrier in rats with brain edema and encephalopathy due to acute hepatic failure. Gastroenterol. Jpn 24(2), 135-142 (1989).
46. Xu J, Ling E-A. Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers. J. Anat. 184, 227-237 (1994).
47. Damment S, Greaves P, Downes N. The toxicology of lanthanum carbonate (Fosrenol®), a novel nonaluminum, noncalcium phosphate binder. Presented at the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, 14-17 November 2003.
48. Jablonski G, Klem KH, Attramadal A et al. Surgically induced uremia in rats. I: effect on bone strength and metabolism. Biosci. Rep. 13(5), 275-287 (1993).
49. Behets GJ, Dams G, Vercauteren SR et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J. Am. Soc. Nephrol. 15, 2219-2228 (2004).
50. Stewart AJ. Administration of a novel phosphate binder, Fosrenol®, with food is associated with good tolerability and low systemic absorption. J. Am. Soc. Nephrol. 13, 386A (2002).
51. Pennick M, Damment SJP, Gill M. The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol®), a novel nonaluminium, noncalcium phosphate binder. Presented at the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, 14-17 November 2003.
52. Evans CH. Biochemistry of the Lanthanides. Plenum Press, NY, USA (1990).
53. Fiddler G, Täubel J, Webster I, Gill M. Lanthanum carbonate does not have a clinically significant effect on the pharmacokinetics of digoxin, warfarin or metoprolol. Presented at the 40th ERA-EDTA World Congress of Nephrology. Berlin, Germany, 9-12 June 2003.
54. Dewberry K, Fox JS, Stewart J, Murray JR, Hutchison AJ. Lanthanum carbonate: a novel noncalcium containing phosphate binder. J. Am. Soc. Nephrol. 9, 560A (1997).
55. Hutchison AJ, Speake M, Al Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol. Dial. Transplant. 19, 1902-1906 (2004).
56. Finn WF, Joy MS, Hladik GA, and the Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin. Nephrol. 62, 193-201 (2004).
57. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. 42, 96-107 (2003).
58. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin. Pract. (2005) (In Press).
59. Finn WF. The new phosphate-binding agent lanthanum carbonate: further evidence of long-term (2-year) efficacy and safety. Presented at the 37th Annual Meeting of the American Society of Nephrology. MO, USA, 27 October - 1 November 2004.
60. Hutchison A, Webster I, for the Lanthanum Study Group. Maintained safety tolerability and efficacy of lanthanum carbonate (Fosrenol®) during long-term therapy in haemodialysis patients. Presented at the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, 14-17 November 2003.
61. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol®) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. 85, S73-S78 (2003).
62. Damment SJP, Gill M, Confer S, Jones C, Pennick M, Webster I. The bone kinetics of lanthanum in dialysis patients treated with lanthanum carbonate for up to 4.5 years. Presented at the 37th Annual Meeting of the American Society of Nephrology. St Louis, MO, USA, 27 October-1 November 2004.
63. Malluche HH, Faugere MC, Wang G, Damment SJP, Webster I. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. Poster presented at the 37th Annual Meeting of the American Society of Nephrology. MO, USA, 27 October - 1 November 2004.
64. Fiddler G. Low systemic absorption of lanthanum and excellent tolerability during administration of 3 g of lanthanum as Fosrenol for 5 days. J. Am. Soc. Nephrol. 13, 751A (2002).
65. Stewart AJ. Fosrenol: a novel noncalcium, nonaluminum phosphate binder is well tolerated when given during or after food intake. J. Am. Soc. Nephrol. 13, 751A (2002).
66. Fiddler G. Fosrenol® (lanthanum carbonate) does not affect the pharmacokinetics of concomitant treatment with warfarin. J. Am. Soc. Nephrol. 13, A749-A750 (2002).
67. Hutchison AJ, Speake M, Dewberry K, Fox JS. Lanthanum carbonate: a novel noncalcium containing phosphate binder in CAPD patients. Perit. Dial. Int. 18, S38 (1998).
68. De Broe ME. Fosrenol (lanthanum carbonate) vs. calcium carbonate for the treatment of hyperphosphatemia: a comparison of the effects on bone using biopsy examination. J. Am. Soc. Nephrol. 13, A769 (2002).
69. Finn WF, Joy MS, Webster I, Gill M. A long-term (2-year) assessment of the safety and efficacy of lanthanum carbonate, a noncalcium, nonaluminum phosphate binder, for the treatment of hyperphosphatemia. Poster presented at the 40th ERA-EDTA World Congress of Nephrology. Berlin, Germany, 9-12 June 2003.
70. Yang WC, Chaing SS, Chen JB. Efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in Chinese chronic renal failure patients. Poster presented at the 36th Annual Meeting of the American Society of Nephrology (ASN). San Diego, CA, USA, 9-12 June 2003.
71. UK Renal Association. Treatment of Adults and Children with Renal Failure. Standards and Audit Measures (Third Edition). UK Renal Association, London, UK (2002).
72. Anon. NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am. J. Kidney Dis. 37(Suppl. 1), S7-S64 (2001).
73. Manns B, Stevens L, Miskulin D, Owen WF, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 66(3), 1239-1247 (2004).
74. Uribarri J. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications. Semin. Dial. 17(5), 349-350 (2004).
75. Knapp S. Bone metabolism and disease - K/DOQI impact on nurses and dietitians. Nephrol. Nurs. J. 31(3), 333-335 (2004).
76. Nicolucci A, Giorgino R, Cucinotta D et al. Validation of the Italian version of the WHO - Well-Being Questionnaire (WHO - WBQ) and the WHO - Diabetes Treatment Satisfaction Questionnaire (WHO - DTSQ). Diabet. Nutr. Metab 17(4), 235-243 (2004).
77. Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). Nephrol. Dial. Transplant. 18(8), 1446-1451 (2003).